bpc 157 clinical trial human randomized Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing Frontiers | Pharmacokinetics, distribution, metabolism,
Description
The study enrolled 617 patients, average age 62, who had never been vaccinated against shingles and were taking a TNF inhibitor for rheumatoid arthritis, psoriatic arthritis, or another condition
Repair: This is where BPC-157 shines
Documentation was accessible and clearly organized
Remarque : une notice n'est pas toujours disponible pour les mdicaments homopathiques
